● 是否需要提交股东会审议：是 ● 日常关联交易对上市公司的影响：本次关联交易为公司日常关联交易，以公 司正常经营业务为基础，以市场价格为定价依据，不影响公司的独立性，不存在损 害公司及股东利益的情形，公司不会因该关联交易对关联方产生依赖。 一、 日常关联交易基本情况 株洲欧科亿数控精密刀具股份有限公司（以下简称"公司"）控股子公司与关 联方共同投资设立控股孙公司欧科亿（山东）新能源科技有限公司，并于 2025 年 6 月 13 日完成工商登记手续。本次登记完成后，江苏锐趋新能源科技有限公司、郯城 欧锐达新能源科技有限公司为持有公司控股孙公司 5%以上股份的法人，同时，扬州 新甬磁机电科技有限公司、郯城锐趋新能源科技有限公司为江苏锐趋新能源科技有 限公司全资子公司。根据《上海证券交易所科创板股票上市规则》的规定及实质重 于形式原则，新增认定江苏锐趋新能源科技有限公司、扬州新甬磁机电科技有限公 司、郯城欧锐达新能源科技有限公司、郯城锐趋新能源科技有限公司为公司关联方。 (一) 日常关联交易履行的审议程序 证券代码：688308 证券简称：欧科亿 公告编号：2025-031 株洲欧科亿数控精密刀具股份有限公司 关 ...

科创板"考生"武汉禾元生物科技股份有限公司（以下简称"禾元生物"）成功过会，距上市仅一步之遥。 这家专注重组蛋白技术的公司，在历经财务资料过期中止等波折后，于今年7月叩响科创板大门，并于7 月4日正式提交注册申请。 募资24亿元，相较于此前募资规模大幅缩水 | 序号 | | | 拟投入募集 | | 早见: 门 元 | | --- | --- | --- | --- | --- | --- | | | 项目名称 | 投资总额 | 资金 | 项目备案批文 | 环评批复 | | | 重组人自蛋白产业化基 | | | 2405-420118- | 武新环管 | | | 地建设项目 | 190,866.57 | 165,752.73 | 04-01-170733 | [2024]2号 | | 7 | 新药研发项目 | 79,369.00 | 64,247.27 | 不适用 | 不适用 | | 3 | 补充流动资金 | 10,000.00 | 10,000.00 | 不适用 | 不适用 | | | 合计 | 280,235.57 | 240,000.00 | | | 来源于禾元生物招股书 显然，重组人白蛋白产业化基地建设 ...

Core Viewpoint - Maanshan Iron & Steel Co., Ltd. has signed a supplementary agreement with China Baowu Steel Group Co., Ltd. to update the transaction limits for the product sales agreement for the years 2025-2027, reflecting the company's current business conditions and the need for enhanced collaboration to address market risks [1][2]. Group 1: Related Transactions Overview - The original product sales agreement was approved at the 2024 sixth extraordinary general meeting, establishing transaction content and upper limits for sales between Maanshan Steel and China Baowu for 2025-2027 [1]. - The supplementary agreement updates the upper limits for sales of products including steel, iron ingots, and other materials, with specific annual limits set for 2025, 2026, and 2027 [3][4]. Group 2: Financial Details of the Supplementary Agreement - The updated sales limits (excluding tax) are as follows: - 2025: RMB 27,641,790,517 - 2026: RMB 39,960,768,539 - 2027: RMB 40,201,124,627 [3][4]. - The procurement limits (excluding tax) are set at: - 2025: RMB 38,301,245,112 - 2026: RMB 79,293,051,022 [3][4]. Group 3: Impact on the Company - The agreement is expected to enhance Maanshan Steel's product sales channels and service quality by leveraging China Baowu's marketing and processing networks, ultimately improving production efficiency and product competitiveness [4][5]. - The collaboration aims to create a marketing synergy that maximizes both parties' strengths, enhancing commercial value and operational efficiency [4][5]. Group 4: Stock Repurchase Plan - The company plans to repurchase and cancel a portion of restricted stock due to unmet performance targets and retirements of certain incentive plan participants [4][5]. - The repurchase will involve 21,423,400 shares at a price of RMB 2.29 per share, totaling RMB 49,135,168, funded by the company's own resources [8][9]. - The stock structure will change post-repurchase, with the total number of restricted shares reduced to zero, while the unrestricted shares remain unchanged [8][9]. Group 5: Legal and Compliance Aspects - The repurchase plan complies with relevant laws and regulations, and necessary approvals have been obtained [10]. - The company will fulfill its disclosure obligations and handle the necessary registration changes following the approval of the repurchase plan [10].

证券代码：605138 证券简称：盛泰集团 公告编号：2025-064 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 盛泰智造集团股份有限公司（以下简称"公司"）分别于 2025 年 4 月 18 日和 2025 年 5 月 13 日召开第三届董事会第十一次会议和 2024 年年度股东大会， 审议通过了《关于变更公司注册资本、修订章程并办理工商变更登记的议案》， 具体内容详见公司于 2025 年 4 月 22 日披露的《盛泰智造集团股份有限公司关于 （公告编号：2025-045）。 变更公司注册资本、修订章程并办理工商变更登记的公告》 近日，公司完成了工商变更登记手续，并取得浙江省市场监督管理局换发的 《营业执照》，变更后的登记信息如下： 转债代码：111009 转债简称：盛泰转债 盛泰智造集团股份有限公司 类型：股份有限公司（港澳台投资、上市） 法定代表人：徐磊 注册资本：伍亿伍仟伍佰伍拾陆万贰仟肆佰壹拾陆人民币元 成立日期：2007 年 05 月 25 日 住所：浙江省嵊州经济开 ...

Group 1 - The core viewpoint of the article is that Wuhan Heyuan Biotechnology Co., Ltd. has been approved for IPO by the Shanghai Stock Exchange, marking it as the 30th company to pass this year [1] - Heyuan Biotechnology is an innovative biopharmaceutical company with a leading global plant-based bioreactor technology platform, focusing on products including pharmaceuticals, pharmaceutical excipients, and research reagents [1][2] - The company plans to issue 89.45 million shares, accounting for 25.02% of the total share capital post-issue, and aims to raise 240 million yuan for projects including the construction of a human serum albumin industrialization base and new drug research and development [2] Group 2 - The controlling shareholder and actual controller of the company is Yang Daichang, who holds 40.29 million shares, representing 15.03% of the total share capital, and indirectly controls an additional 10.05 million shares, totaling 18.78% [2] - The main questions raised during the listing committee meeting included inquiries about the advanced nature of the core technologies, market space estimation for the drug HY1001, and safety compliance measures for the production of medicinal rice [3]

一、基本信息 公司是一家创新型生物医药企业，拥有全球领先的植物生物反应器技术平台。公司建立了"一个独特植物表达体系，两个技术平台"的核心技术体系： 利用水稻胚乳细胞生物反应器高效重组蛋白表达平台（OryzHiExp）和重组蛋白纯化技术平台（OryzPur），建立了完善的药品、药用辅料及科研试剂 的产业化体系。公司产品主要包括药品、药用辅料以及科研试剂。 公司前身有限公司成立于2006年11月，2014年12月整体变更为股份有限公司，发行前总股本为26,804.8646万股，拥有2家全资子公司。截至2024年末， 员工总计178人。 二、控股股东、实际控股人 文/梧桐数据中心 7月1日，武汉禾元生物科技股份有限公司科创板IPO申请获得上交所上市委审核通过。 6月18日，中国证监会主席吴清在2025陆家嘴论坛上宣布，将重 启未盈利企业适用科创板第五套标准上市。禾元生物IPO今天成功过会，是落实证监会《关于在科创板设置科创成长层增强制度包容性适应性的意见》 的典型案例。 单位：万元 | | 科创板 | | | | | | --- | --- | --- | --- | --- | --- | | 公司简称 | 主营 ...

Core Viewpoint - Zhejiang Weixing Industrial Development Co., Ltd. has experienced a decline in stock price over three consecutive trading days, with a cumulative drop of -1.27% as of June 30 [1] Company Overview - Founded in 1988, Zhejiang Weixing specializes in apparel and bag accessories, including buttons, zippers, metal products, plastic products, webbing, ropes, and labels [1] - The company is a leading player in China's apparel accessories industry and holds significant positions in various industry associations, including being the vice president unit of the China Daily Goods Industry Association's Button Branch and the vice president of the China Hardware Products Association's Zipper Branch [1] - Weixing is recognized as the first publicly listed company in the button and zipper industry in China and is a key contributor to the drafting of industry standards [1] Financial Performance - According to financial reports, GF Fund's "GF Stable Growth Mixed A" is among the top ten shareholders of Weixing, having increased its holdings in the first quarter of this year [1] - The fund has achieved a year-to-date return of 2.46%, ranking 16th out of 59 in its category [1]

Core Insights - The 2025 Shanghai International Functional Textiles (Autumn/Winter) Exhibition will take place on August 6-7, 2025, at the Shanghai World Expo Exhibition and Convention Center, showcasing the latest trends and innovations in functional textiles [2][49] - The exhibition will feature over 200 renowned domestic and international innovative companies, including 3M, Polartec, and Lycra, among others [2] - The event aims to integrate cutting-edge market trends and provide a systematic platform for brand buyers to explore innovative functional materials [9] Group 1: Exhibition Highlights - Exhibiting companies will present their latest research and development achievements, showcasing diverse functional products such as waterproof, breathable, and antibacterial materials [6][24] - The exhibition will serve as a benchmark platform for the global functional textile industry, evolving into an international hub for industry collaboration and innovation incubation [7][22] - The Trend Forum will explore innovations across all categories of functional textiles, including smart temperature regulation and eco-friendly materials, in collaboration with leading trend organizations [10][12] Group 2: Innovation and Sustainability - The Innovation Forum will highlight groundbreaking technologies and materials that have not yet reached large-scale commercial application, focusing on green materials and high-performance fabrics [18] - The exhibition will feature a special area dedicated to wool trends, showcasing the innovative applications of Merino wool in functional apparel, emphasizing its sustainable and high-performance characteristics [44][47] - The event will also include expert talks and workshops, providing industry insights and application solutions to attendees [21][22] Group 3: Market Trends and Consumer Insights - The rise of global outdoor lifestyles and the awakening of women's self-awareness are influencing the development direction of the textile industry, creating new value propositions and opportunities [25][31] - The exhibition will focus on market demand hotspots, presenting the latest research results and commercial applications in the functional textile field [24][31] - The event aims to inspire the industry with forward-looking ideas and market opportunities, promoting the integration of textile technology and fashion design [47]

此外，买卖合同虽然约定"付款前需先开具发票"，但支付货款与开具发票是不同性质的合同义务，前者 属于主要义务，后者仅是附随义务，二者不具有对等关系。同时，民法典和批复的规定也明确支持卖方 的诉讼请求，A建设公司无权在B新材料公司已经依约履行主要义务的情况下，仍然以第三方未向其付 款为由拒绝支付货款。 最终，法院判决支持了某新材料公司要求某建设公司支付剩余货款的诉讼请求。宣判后，双方均未提起 上诉，现一审判决已经生效。 A建设公司庭上辩称，合同中两条"特别约定"：卖方依据买方认可的金额先开具增值税发票，卖方未提 供发票或发票不符合规范的，买方可以拒绝付款且不承担违约责任；买方应向卖方支付的所有合同款项 均需在本工程的发包方向买方支付相应款项后，方能支付给卖方。因发包方尚未付款，且B公司有部分 发票未开，故其拒付"于约有据"。 北京市西城区人民法院经审理认为，对于买卖合同约定A建设公司在收到发包方向其支付货款后方能向 B新材料公司支付的内容，自2024年8月27日起施行的《最高人民法院关于大型企业与中小企业约定以 第三方支付款项为付款前提条款效力问题的批复》(以下简称"批复")规定：大型企业在建设工程施工、 采购货 ...

Core Viewpoint - Aoke Co., Ltd. collaborates with Shutai Shen to provide pharmaceutical excipient polyethylene glycol products [1] Group 1 - Aoke Co., Ltd. stated on its interactive platform that Shutai Shen (Beijing) Biopharmaceutical Co., Ltd. is a downstream customer of its subsidiary Aoke Pharmaceutical [1] - Shutai Shen primarily purchases polyethylene glycol products from Aoke Pharmaceutical [1]